Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice, 2e (May 15, 2023)_(1635930553)_(Oncology Nursing Society).pdf

Contents Preface Section I. Professional Practice Considerations Chapter 1. Professional Practice Considerations A. Scope and standards B. Professional education C. Policies and procedures D. Antineoplastic medication safety E. Quality and safety monitoring References Chapter 2. Ethical and Legal Issues A. Ethical issues B. Legal issues related to cancer therapy References Chapter 3. Patient Education A. Patient education overview B. Short-term outcomes of patient education C. Long-term outcomes of patient education D. Barriers to patient education E. Methods of patient education F. Scope of information G. Documentation References Section II. Cancer and Cancer Treatment Chapter 4. Overview of Cancer and Cancer Treatment A. Definition of cancer B. The Cancer Care Continuum framework C. Cancer staging and grading D. Cancer treatment modalities E. Treatment approaches F. Treatment strategies G. Measuring response H. Factors affecting treatment response I. Adherence J. Toxicity grading and documentation References Chapter 5. Clinical Trials and Drug Development A. Clinical research B. Drug and biologic development process C. Expanded access References Section III. Cancer Therapeutics Chapter 6. Chemotherapy A. Chemotherapy in the treatment of cancer B. Classification of chemotherapy agents C. Chemotherapy classifications D. Combination chemotherapy principles References Chapter 7. Hormone Therapy A. Hormone therapy in the treatment of cancer B. Cancers treated with hormone therapy C. Hormone treatment categories References Chapter 8. Targeted Therapy A. Targeted therapies in the treatment of cancer B. Adverse effects of targeted therapies C. Drug-drug interactions References Chapter 9. Principles of the Immune System A. Overview of immunology B. Types of immune response C. Organs of the immune system D. Cells of the immune system E. Immune system proteins and receptors F. Phases of immune response G. Tumor escape mechanisms References Chapter 10. Immunotherapy A. Overview B. Modalities of immunotherapy C. General patient and family education References Section IV. Treatment Administration and Safety Chapter 11. Administration Considerations A. Components of safe and effective administration of cancer therapies B. Pretreatment C. Chemotherapy, targeted therapy, and immunotherapy dosing D. Verification E. Routes of chemotherapy, immunotherapy, and targeted therapy administration References Chapter 12. Safe Handling of Hazardous Drugs A. Safe handling and disposal of hazardous drugs B. Definition C. Antineoplastic drugs D. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings E. NIOSH List of Hazardous Drugs in Healthcare Settings F. Immunotherapy G. Routes of occupational exposure H. Hierarchy of hazard controls I. Guidelines for PPE J. Storage and labeling K. Safe handling precautions during compounding L. Transporting HDs M. Safe handling precautions during administration N. Special precautions for radiopharmaceuticals O. Handling body fluids P. Handling patient linens Q. Disposal of HDs and materials contaminated with HDs R. Procedures following acute HD exposure S. Spill management T. Requirements for policies regarding the handling of HDs References Chapter 13. Infusion-Related Complications A. Complications during or shortly after parenteral administration of cancer treatment B. Extravasation of vesicants resulting in potential tissue damage C. Irritation D. Flare reaction E. Acute infusion-related reactions F. Patient and caregiver education References Section V. Treatment-Related Complications Chapter 14. Myelosuppression A. Overview B. Types of cytopenias References Chapter 15. Gastrointestinal and Mucosal Toxicities A. Nausea and vomiting B. Anorexia and cachexia C. Diarrhea D. Colitis E. Pancreatitis F. Mucositis G. Perirectal cellulitis H. Constipation References Chapter 16. Cardiovascular Toxicities A. Overview B. Conduction pathway disorders C. Vascular abnormalities: hypertension D. Venous thromboembolism E. Coronary artery disease F. Left ventricular dysfunction and heart failure G. Myocarditis References Chapter 17. Pulmonary Toxicities A. Overview B. ILD C. Diffuse alveolar hemorrhage D. Acute promyelocytic leukemia treatment-related differentiation syndrome E. Pleural effusions F. Patient and family education References Chapter 18. Hepatic Toxicities A. Overview B. Pathophysiology C. Incidence D. Risk factors E. Clinical manifestations F. Pathologic manifestations associated with drug toxicity G. Assessment H. Collaborative management I. Patient and family education References Chapter 19. Genitourinary Toxicities A. Overview B. Antineoplastic-associated genitourinary toxicities C. Drug-specific considerations References Chapter 20. Altered Sexual and Reproductive Functioning A. Alterations in sexual functioning B. Alterations in reproductive functioning References Chapter 21. Cutaneous Toxicities and Alopecia A. Cutaneous toxicity B. Alopecia References Chapter 22. Endocrine Toxicities A. Overview B. Drug-specific endocrinopathies C. Immune checkpoint inhibitor-related endocrinopathies References Chapter 23. Fatigue A. Overview B. Pathophysiology C. Incidence D. Assessment E. Collaborative management F. Principles of patient and family education and care planning References Chapter 24. Neurologic Toxicities A. Overview B. Radiation-induced CNS toxicity C. Radiation-induced peripheral nervous system toxicity D. Chemotherapy-induced CNS toxicity E. Peripheral neuropathy F. Common antineoplastics conferring increased neurotoxicity G. Risk factors and prophylaxis H. Cognitive impairment I. Patient and family education References Chapter 25. Ocular Toxicities A. Overview B. Pathophysiology C. Incidence D. Risk factors E. Clinical manifestations F. Assessment G. Collaborative management H. Patient and family education References Section VI. Post-Treatment Chapter 26. Post-Treatment and Survivorship Care A. Overview B. Cancer survivorship care C. Long-term and late effects of cancer treatment References Appendices Appendix A. Clinical Practicum Evaluation: Part I Appendix B. Clinical Practicum Evaluation: Part II Appendix C. Sample Chemotherapy Order Template Appendix D. Antineoplastic Treatment Safety Checklist Appendix E. Consent for Antineoplastic Drug Treatment Appendix F. Distress Thermometer Appendix G. Hazardous Drug Administration Safe Handling Checklist Appendix H. Extravasation Appendix I. Vesicant Drug Extravasation Record Index "Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice"-- Provided by publisher